 |
|
|
|
|
|
|
|
 |
Results for 'Gene Therapy' |
|
|
| Title |
 |
Publication Date |
|
Price |
|
Relevance |
 |
|
|
|
|
Gene Therapy
Technologies, Markets and Companies
|
September 2008 |
£1435 |
100 % |
Gene Therapy: Industry Background Report
List of Companies
|
October 2005 |
£345 |
96 % |
Pipeline Insight: PAD
Gene Therapy Going Out on a Limb
|
November 2004 |
£6000 |
70 % |
Drug Delivery in Cancer
Technologies, Markets and Companies
|
September 2008 |
£2010 |
23.5 % |
Biotechnology in Australia
IBISWorld Industry Report
|
August 2007 |
£460 |
23 % |
Global Biotechnology
IBISWorld Industry Report
|
September 2007 |
£505 |
22 % |
Cell Therapy
Technologies, Markets and Companies
|
September 2008 |
£3020 |
21 % |
Biotechnology in the US
IBISWorld Industry Report
|
January 2007 |
£435 |
20.5 % |
Personalized Medicine
scientific & commercial aspects
|
September 2008 |
£2680 |
18.5 % |
The Endometrium: Molecular, Cellular and Clinical Perspectives
2nd edition
|
December 2007 |
£280 |
18.2 % |
Gene Express, Inc. Product Pipeline Analysis
|
August 2008 |
£505 |
18.2 % |
Superficial Bladder Cancer
Current Management and Future Trends
|
November 2005 |
£1085 |
16.8 % |
Drug Discovery
Current trends and future prospects
|
February 2001 |
£300 |
15.5 % |
Multiple Myeloma
|
October 2007 |
£105 |
15.4 % |
Proteomics
Technologies, Markets and Companies
|
September 2008 |
£2345 |
14.5 % |
Cancer Drug Resistance
2008
|
September 2008 |
£1675 |
14.5 % |
Triple Progress Analysis: Melanoma, Colorectal & Lung Cancer
|
March 2006 |
£2895 |
14 % |
China Bio-Pharma Profiles 2005
|
November 2005 |
£495 |
13.5 % |
Stakeholder Opinions
Novel Therapeutic Approaches in Cardiovascular Medicine - Lack of Market Prospects for Biologics Expose An Opportunity for Cell and Gene Therapies
|
July 2008 |
£3800 |
13.3 % |
Dircetory of Clinical Research Companies in India
|
January 2008 |
£600 |
13 % |
Emerging U.S. Biopharmaceutical Companies
New Drug R&D and Investment /Partnership Opportunities
|
April 2001 |
£735 |
12.95 % |
DNA/RNA Therapies
Translating the Genome into a $1.2bn Market by 2010
|
February 2005 |
£4000 |
12.6 % |
Tercica Inc
Premium Company Profile
|
December 2007 |
£265 |
12.5 % |
Bioms Medical Corp
Premium Company Profile
|
April 2008 |
£265 |
12.5 % |
Pipeline Insight: Nociceptive Pain
Safety Profile Uppermost in Crowded Market
|
October 2004 |
£6000 |
12 % |
Bioinformatics
Technical Status and Market Prospects
|
August 2005 |
£3045 |
12 % |
Pharmaceutical Biotechnology: Fundamentals and Applications
Third Edition
|
October 2007 |
£115 |
11.9 % |
Stakeholder Opinions: Cystic Fibrosis
|
March 2006 |
£2195 |
11.55 % |
China Pharmaceutical Guidebook Series - Vol 4
A Guidebook of Registration Application for Imported Traditional Chinese Medicines and Natural Medicines
|
February 2007 |
£505 |
11.2 % |
Pharmaceutical Biotechnology
Drug Discovery and Clinical Applications
|
February 2004 |
£115 |
11.2 % |
Neuroprotection
Drugs, Markets and Companies
|
September 2008 |
£1435 |
11 % |
Pipeline Insight: Parkinson's Disease and Restless Legs Syndrome
Reformulations set to drive near-term growth
|
August 2006 |
£8695 |
11 % |
Nanobiotechnologies
applications, markets and companies
|
September 2008 |
£1435 |
11 % |
Cancer Drug Discoveries: Breast Cancer
|
August 2005 |
£795 |
10.85 % |
Top Companies and Products in the RNA/DNA Therapy Products Market Forecasts:
The Challenge Of Turning Technology Into Therapy
|
July 2007 |
£1999 |
10.5 % |
Biotechnology and Biopharmaceuticals
Transforming Proteins and Genes into Drugs
|
July 2003 |
£55.95 |
10.5 % |
Textbook of Interventional Cardiovascular Pharmacology
|
April 2007 |
£140 |
10.15 % |
Molecular Imaging Comes of Age
Applications and Impacts in Discovery, Clinical Trials, and Medical Practice
|
October 2004 |
£1950 |
10 % |
Stakeholder Opinions: Alpha 1 Antitrypsin Deficiency
|
January 1970 |
£2000 |
9.8 % |
Cancer Therapeutics Markets
|
May 2008 |
£2280 |
9.45 % |
Drug Delivery: Principles and Applications
|
May 2005 |
£61.5 |
9.1 % |
Stakeholder Opinions: Non-Hodgkin's Lymphoma
Immunotherapy Stimulates the Market
|
October 2004 |
£2000 |
9.1 % |
Cardiovascular Drug Delivery
Technologies, markets and companies
|
September 2008 |
£1475 |
8.75 % |
Analytical R&D Tool - Analysis of Prostate Cancer R&D
The Complete Guide
|
February 2004 |
£3355 |
8.5 % |
Protein Kinase Inhibitors in Oncology: Drug Pipeline Update 2006
Drug Pipeline Update 2007
|
May 2007 |
£1260 |
8.5 % |
Islet Transplantation and Beta, Cell Replacement therapy
|
April 2007 |
£145 |
8.4 % |
Drug Targets for Breast Cancer
|
January 2006 |
£1095 |
8.4 % |
Osmetech plc Product Pipeline Analysis
|
August 2008 |
£505 |
8.4 % |
Apoptosis: Promise or deception?
|
May 2005 |
£1635 |
8.4 % |
Melanoma - Targeted Therapeutics
|
July 2007 |
£1635 |
8.4 % |
Currently Druggable in Breast Cancer: A Drug Target Competitive Analysis
|
August 2008 |
£1295 |
8.4 % |
Currently Druggable in Prostate Cancer
A Drug Target Competitive Analysis
|
September 2008 |
£1295 |
8.4 % |
Carotid Atherosclerotic Disease: Pathologic Basis for Treatment
|
April 2007 |
£125 |
8.05 % |
Siemens Medical Solutions Medical Device Company Intelligence Report
|
February 2007 |
£395 |
8 % |
Renal Cancer Drug Pipeline Update 2007
|
May 2007 |
£1260 |
8 % |
Prostate Cancer - A Therapeutic & Competitive Insight
Drug Pipeline Update 2007
|
May 2007 |
£1260 |
8 % |
CRC Drug Pipeline Update 2005
|
May 2007 |
£1260 |
8 % |
Orthopedic Biomaterials, The World Market, 2nd Edition
|
September 2007 |
£2345 |
7.35 % |
Drug Delivery Technology: Revolutionizing Cardiovascular Therapies
|
July 2007 |
£945 |
7.35 % |
Orthopedic Biomaterials, The World Market
2nd Edition
|
September 2007 |
£2345 |
7.35 % |
Drug Delivery in Central Nervous System Diseases
technologies,markets and companies
|
September 2008 |
£900 |
7.35 % |
Antibodies in Oncology
Drug Pipeline Update 2007
|
May 2007 |
£1260 |
7 % |
Lymphoma Drug Pipeline Update 2006
|
May 2007 |
£1260 |
7 % |
Diagnostics and Therapeutics for Genetic Diseases
|
April 2006 |
£3255 |
7 % |
Wound Care Markets, 3rd. Edition, Vol. I
Skin Ulcers
|
July 2007 |
£2010 |
7 % |
Vascular Targeting and Anti-angiogenesis in Oncology
Drug Pipeline Update 2007
|
May 2007 |
£1260 |
7 % |
Gen-Probe Incorporated Product Pipeline Analysis
|
August 2008 |
£505 |
7 % |
Pancreatic Cancer Drug Pipeline Update 2007
|
May 2007 |
£1260 |
7 % |
Liver Cancer Drug Pipeline Update 2007
|
May 2007 |
£840 |
7 % |
Neurodegenerative Drug Futures
|
February 2005 |
£995 |
7 % |
Bladder Cancer Drug Pipeline Update 2007
|
May 2007 |
£840 |
7 % |
The Future of Targeted Therapeutics
Key Technologies, New Therapy Area Applications and Leading Players
|
March 2008 |
£1995 |
6.65 % |
Drug Delivery Technology: Revolutionizing Diabetes Treatment
|
September 2007 |
£945 |
6.65 % |
Triple Analysis: Melanoma Therapeutics, Antibodies and Vaccines in Oncology
|
August 2006 |
£2895 |
6.65 % |
Drug Delivery Technology
Revolutionizing Diabetes Treatment
|
September 2007 |
£945 |
6.65 % |
Impact of Genomics on Clinical Trials and Medical Practice, The
|
April 2006 |
£1845 |
6.65 % |
Emerging Cancer Therapies
Markets and Business Opportunities
|
June 2002 |
£875 |
6.65 % |
Lead Optimization Strategies
An analysis of novel molecular targets to develop innovative new therapeutics
|
January 2005 |
£1495 |
6.65 % |
Ovarian Cancer Drug Pipeline Update 2007
|
May 2007 |
£1260 |
6.5 % |
Hematological Cancers Drug Pipeline Update 2006
|
May 2007 |
£1680 |
6.5 % |
Brain Cancer Drug Pipeline Update 2007
|
May 2007 |
£1890 |
6.5 % |
Immunotherapy in Oncology
Drug Pipeline Update 2007
|
May 2007 |
£1680 |
6.5 % |
Apoptosis in Oncology
Drug Pipeline Update 2007
|
May 2007 |
£1260 |
6.5 % |
Melanoma Drug Pipeline Update 2007
|
May 2007 |
£1260 |
6.5 % |
Leukemia Drug Pipeline Update 2006
|
May 2007 |
£1260 |
6.5 % |
Breast Cancer Drug Pipeline Update 2006
|
May 2007 |
£1260 |
6.5 % |
Non-Antibody Based Cancer Vaccines: Drug Pipeline Update 2006
Drug Pipeline Update 2007
|
May 2007 |
£1260 |
6.5 % |
Analysis of the Pharmaceutical Market to 2012 - Segmented by Drug Target Family
Sales & Marketing
|
October 2007 |
£3800 |
6.3 % |
Cell Therapy Markets
|
July 2007 |
£2280 |
6.3 % |
World Neurodegeneratives Disease Markets
|
February 2005 |
£1499 |
6.3 % |
Hematological Cancer Therapeutics
Pipelines and Competition
|
September 2005 |
£2140 |
6.3 % |
Pipeline Insight: Breast Cancer
Recent approvals increase pressure on pipeline candidates
|
April 2008 |
£6000 |
6.3 % |
Animal Biotechnology
Technologies, Markets and Companies
|
September 2008 |
£900 |
6.3 % |
Lung Cancer Drug Pipeline Update 2006
|
May 2007 |
£1260 |
6 % |
Cancer Stem Cells
Emerging Therapeutic, Diagnostic and Market Opportunities (2008)
|
June 2008 |
£1599 |
5.95 % |
Pipeline Insight: Molecular Targeted Cancer Therapies Can anything else revolutionize the market?
- Cancer
|
October 2007 |
£7600 |
5.95 % |
Nitric Oxide
Therapeutics, Markets and Companies
|
September 2008 |
£1005 |
5.95 % |
Impact of Pharmacogenomics on Public Healthcare Policy
Educating Patients, Payors and Healthcare Providers
|
March 2008 |
£1995 |
5.95 % |
Cancer Cell Therapy Markets
|
March 2008 |
£2280 |
5.95 % |
Pipeline Insight: Migraine
Innovation essential as weak late-stage pipeline fails to hold off the impact of triptan patent expiries
|
December 2006 |
£6000 |
5.95 % |
Antiviral Therapeutics
Technologies, Markets and Companies
|
September 2008 |
£1880 |
5.95 % |
Neurogenomics and Neurotherapeutic Strategies
New Directions in Platforms, Targets, and Therapeutic Approaches
|
February 2005 |
£1950 |
5.95 % |
RNAi
Technologies, Markets and Companies
|
September 2008 |
£2010 |
5.95 % |
New Developments in Insulin Delivery Systems (2006)
|
June 2006 |
£670 |
5.95 % |
Latest Chinese Regulations for Imported Drug Registration
China Pharmaceutical Guidebook
|
June 2008 |
£935 |
5.6 % |
Modern Biopharmaceuticals
Design, Development and Optimization, 4 Volumes
|
September 2005 |
£440 |
5.6 % |
Novel Targets in Drug Discovery
A new era in therapy
|
April 2004 |
£595 |
5.6 % |
Cancer Drug Discoveries
What the Future Holds
|
August 2005 |
£1995 |
5.6 % |
Pharmaceutical Regulatory Affairs in The Eu & US
|
January 2006 |
£1095 |
5.6 % |
Stakeholder Opinions: Head and Neck Cancer
Innovatives to Change the Face of Treatment
|
November 2007 |
£2000 |
5.6 % |
Diabetes Drug Pipeline
Competitor Analysis
|
November 2008 |
£410 |
5.5 % |
Pipeline Insight Asthma/COPD/Allergic Rhinitis
As Patents Expire, Novel Combinations Inspire
|
April 2005 |
£6000 |
5.25 % |
Cancer Drug Discoveries: Prostate Cancer
|
August 2005 |
£795 |
5.25 % |
Stem Cell Therapies and Regenerative Medicine
Current Applications and Future Possibilities
|
December 2005 |
£3045 |
5.25 % |
Burger's Medicinal Chemistry and Drug Discovery
6 Volume Set
|
March 2003 |
£1331 |
5.25 % |
Outlook for RNAi, 2007
siRNA and miRNA in biology, diagnostics and therapeutics
|
June 2007 |
£1495 |
5.25 % |
Indian Biotechnology
|
January 2008 |
£600 |
5.25 % |
Neurodegenerative Disease Drug Market Analysis and Forecasts 2007
|
June 2007 |
£1999 |
5.25 % |
World Market for In Vitro Diagnostics 2005; The
|
January 2005 |
£1299 |
5.25 % |
Defending Brand Revenue
Pharmaceutical Lifecycle Management Planning
|
July 2005 |
£2605 |
5.25 % |
Convergence of Biomarkers and Diagnostics, The
Therapy Area Analyses, Key Products and Future Trends
|
April 2008 |
£1995 |
5.25 % |
Parkinson's Disease Market analysis and forecasts
2008-2012, 2017 & 2022
|
January 2008 |
£1499 |
5.25 % |
Cancer Therapeutics: The Worldwide Market
The Worldwide Market , 2nd Editon
|
February 2007 |
£2680 |
5.25 % |
Advanced Drug Delivery Systems: Probing the Route to Growth
New Developments, New Technologies, Companies and Trends
|
October 2001 |
£955 |
5.25 % |
Opportunities in Stem Cell Research and Commercialization
Technology advances, regulatory impact and key players
|
April 2006 |
£1495 |
4.9 % |
Labeling and Linkage Agents for Immunoassays and Gene Probes
|
April 2006 |
£3255 |
4.9 % |
The Outlook For RNAi
Accelerating drug discovery and the development of RNAi therapeutics
|
January 2005 |
£1495 |
4.9 % |
Pain Therapeutics
Drugs, Markets and Companies
|
September 2008 |
£1075 |
4.9 % |
Pipeline And Commercial Insight: Parkinson's Disease
Market To Grow As First Round Of Lifecycle Management Strategies Succeed
|
September 2007 |
£7600 |
4.9 % |
Innovation in Drug Delivery
The future of nanotechnology and non-invasive protein delivery
|
November 2006 |
£1495 |
4.9 % |
Drug Delivery Technology: Revolutionizing CNS Therapies
|
December 2007 |
£945 |
4.9 % |
Obesity Drug Discoveries: what the future holds
|
August 2007 |
£1425 |
4.9 % |
Obesity Drug Discoveries: what the future holds + Obesity Tracker
|
August 2007 |
£995 |
4.9 % |
AMD Market Outlook to 2012
|
March 2007 |
£1299 |
4.9 % |
Innovations in Cancer
Novel Therapeutics, New Diagnostics and Future R&D Strategies
|
February 2007 |
£1495 |
4.9 % |
Stakeholder Opinions: Primary Brain Cancer
Temozolomide Turns Heads
|
July 2007 |
£2000 |
4.55 % |
Stakeholder Opinions: Melanoma
Lucrative commercial opportunities persist
|
December 2006 |
£2000 |
4.55 % |
Transdermal Drug Delivery
Technologies, Markets, and Companies
|
September 2008 |
£1675 |
4.55 % |
Pipeline Insight: HIV
Extending treatment options
|
September 2006 |
£6000 |
4.55 % |
Triple Analysis: Apoptosis Agents, Antibodies and Vaccines in Oncology
|
December 2006 |
£2895 |
4.55 % |
Pharmaceutical Regulatory Affairs in the EU and US
|
December 2006 |
£1095 |
4.55 % |
Market for Advanced Wound Care Technology; The
|
January 2007 |
£3255 |
4.55 % |
Pipeline Insight: Non-insulin antidiabetics Incretin mimetics leaders in a diverse pipeline
|
May 2008 |
£6000 |
4.55 % |
Competitive Outlook on Non-Antibody Based Cancer Vaccines
|
August 2006 |
£1635 |
4.55 % |
Organ Transplant Immunosuppressive Markets
|
January 2008 |
£2345 |
4.55 % |
Stakeholder Opinions: Acute Leukemias
Persistent unmet needs confer significant commercial opportunity
|
April 2006 |
£2170 |
4.55 % |
Wound Care, 3rd Edition, Vol. II: Burns
|
September 2007 |
£2010 |
4.55 % |
World market for cancer vaccines 2007-2012
|
January 2007 |
£1999 |
4.55 % |
Innovations in CNS
Novel therapeutics and future R&D strategies
|
January 2007 |
£1495 |
4.2 % |
Competitive Outlook on HCV
What to Know& Expect in R&D and Business Development
|
June 2004 |
£840 |
4.2 % |
Migraine
A market focus
|
August 2004 |
£885 |
4.2 % |
Top 7 Cancer Indications
Therapeutic & Competitive Insights
|
January 2007 |
£5835 |
4.2 % |
Pipeline Insight: Antidyslipidemics
The Power of Two
|
August 2005 |
£6000 |
4.2 % |
Pipeline Insight: Heart failure Week pipeline dominated by new indications and add-on diuretics
|
August 2007 |
£6000 |
4.2 % |
The Deployment of Antibody Technologies for the Advancement of Cancer Therapeutics
|
April 2008 |
£1505 |
4.2 % |
Stem Cell Research
|
January 2008 |
£2850 |
3.85 % |
Enzymes
US industry forecasts to 2010 & 2015
|
July 2006 |
£2885 |
3.85 % |
Personalized Medicine
|
August 2007 |
£1340 |
3.85 % |
Molecular Diagnostics Markets
|
September 2008 |
£2280 |
3.85 % |
Emerging Technologies in Spinal Motion Preservation
|
October 2006 |
£1295 |
3.85 % |
RNA Interference Markets
|
September 2008 |
£1340 |
3.85 % |
Nanotechnology in Life Science Applications
|
October 2005 |
£3045 |
3.85 % |
Alzheimer disease
new drugs, markets and companies
|
September 2008 |
£1880 |
3.85 % |
Proteins
Strategies for Optimizing Drug Discovery
|
January 2004 |
£1000 |
3.85 % |
Executive Guide to Molecular Imaging; The
|
April 2005 |
£395 |
3.5 % |
Preclinical Cancer Therapeutics 2007
Decoding Next Generation Drug Targets for Market Success
|
December 2006 |
£1600 |
3.5 % |
Pipeline Insight: Osteoarthritis
The Wait for a DMOAD Continues
|
November 2006 |
£6000 |
3.5 % |
Targeted Therapies in Oncology
A World Review
|
December 2006 |
£4155 |
3.5 % |
Cancer Biomarkers
Enhancing diagnostic, therapeutic and developmental strategies
|
May 2006 |
£2195 |
3.5 % |
Drug Delivery Technologies: Players, products & prospects to 2015
|
November 2007 |
£1795 |
3.5 % |
Stakeholder Insight: Atherosclerosis
HDL, ApoA-I, Carotid MRI and 64-slice CT offer opportunities for future treatment
|
December 2006 |
£8000 |
3.5 % |
New Concepts in Cancer Therapeutics
|
December 2005 |
£2055 |
3.5 % |
Beyond the Blockbuster Drug
Strategies for nichebuster drugs, targeted therapies and personalized medicine.
|
February 2005 |
£1495 |
3.5 % |
Molecular Diagnostics
Technologies, Markets and Companies
|
September 2008 |
£3020 |
3.5 % |
A Practical Guide to Biopharmaceutical Manufacturing
|
January 2006 |
£1095 |
3.5 % |
Pipeline Insight: Cancer Overview
Increasing Diversity Offers Both High Risk And Reward
|
September 2007 |
£7600 |
3.15 % |
Triple Progress Analysis: Lymphoma Therapeutics, Protein Kinase Inhibitors & Therapeutic Antibodies
|
May 2006 |
£2895 |
3.15 % |
Global Biotech Report 2006, The
The rise of the Biotech blockbusters
|
September 2006 |
£4999 |
3.15 % |
What's Hot in Cancer Drug R&D?
|
July 2006 |
£295 |
3.15 % |
GSK's Cervarix
A Future Blockbuster of 2007
|
March 2007 |
£1999 |
3.15 % |
Pharmaceutical R&D Productivity
The Path to Innovation
|
October 2005 |
£1945 |
3.15 % |
Drug Delivery Systems
US Market Outlook, Advances for Pharma, Biotech & Medical Devices
|
September 2006 |
£1540 |
3.15 % |
Triple Analysis: Protein Kinase Inhibitors, Antibodies and Vaccines in Oncology
|
August 2006 |
£2895 |
3.15 % |
Stakeholder Insight: Supportive Care in Cancer Treatment
Some first-generation products proving difficult to dislodge
|
October 2006 |
£8000 |
2.8 % |
Chemotherapy Market Insights, 2006-2016
A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities
|
April 2006 |
£1900 |
2.8 % |
Pharmacogenomics: New Technologies
In the Development of Personalized Therapies
|
August 2005 |
£3045 |
2.8 % |
The Global Market for Advanced Wound Care Products 2007
|
March 2007 |
£695 |
2.8 % |
Innovations in Cardiovascular Disease Management
Latest surgical procedures, drugs and medical devices
|
September 2007 |
£1495 |
2.8 % |
Companion Diagnostics in Personalized Medicine and Cancer Therapy
|
April 2008 |
£2280 |
2.8 % |
Epigenomics
Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics
|
March 2007 |
£3255 |
2.45 % |
World Market for Neurotherapeutic Drugs; The
|
September 2005 |
£2345 |
2.1 % |
Blood
The Worldwide Market for Blood Products, Blood Testing, Blood Equipment, and Synthetic Blood Products
|
September 2006 |
£2615 |
2.1 % |
Therapeutics for Inflammatory Diseases
Current Challenges and Future Market
|
March 2006 |
£3255 |
2.1 % |
Clinical Trials Business; The
|
August 2006 |
£3255 |
2.1 % |
Apoptosis
|
January 2008 |
£1945 |
2.1 % |
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Breast- and Prostate Cancer
|
June 2007 |
£4345 |
2.1 % |
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Leukemias and Lymphomas
|
June 2007 |
£4345 |
2.1 % |
In-Vitro Diagnostics Market Report & Analysis 2008-2023
|
June 2008 |
£1499 |
1.75 % |
In Vitro Diagnostics Market Report & Analysis 2008-2023
|
June 2008 |
£1499 |
1.75 % |
Philips Medical Systems Medical Device Company Intelligence Report
|
December 2005 |
£295 |
1.75 % |
Global Market for Advanced Wound Care Products 2008, The
A complete review of this fast growing, highly innovative sector
|
April 2008 |
£695 |
1.75 % |
The Executive Guide to Molecular Imaging
|
July 2007 |
£595 |
1.4 % |
PAREXEL's Bio/Pharma R&D Statistical Sourcebook 2008/2009
|
June 2008 |
£285 |
1.4 % |
Live-Licensing & In-life Testing
R&D Processes and Regulation for New Drugs, 2008-2020
|
January 2008 |
£1499 |
1.4 % |
Parexel's Pharmaceutical R&D Statistical Sourcebook 2007/2008
|
May 2007 |
£285 |
1.4 % |
|
|
|
|
